



ACN 010 126 708

ASX Release
30 January 2015

DECEMBER QUARTER 2014 APPENDIX 4C

Adelaide, 30 January, 2015: Reproductive Health Science Limited (ASX:RHS) ("RHS" or the "Company") announces its fourth quarter cash flow report for the year ending 31 December 2014.

Highlights

- Cash on hand at 31 December 2014 amounted to \$1.52 Million.
- Operating expenses for the quarter totalled \$444K, with continued progress made on the Company's EmbryoCollect™ product line.
- Year to date, the Company invested \$157K into property plant and equipment, principally relating to the purchase of a higher capacity Arrayjet Microarrayer printer, ensuring the Company has sufficient capacity to roll out its EmbryoCollect™ product line. The Company has secured asset financing for the microarray printer which will see \$141k of printer instalments repaid to the Company in February 2015.
- R&D Tax Credit claim for July 2013 to April 2014 has been approved by the Australian Taxation Office; payment of \$157k is anticipated in February 2015. A further claim of \$57k for R&D expenditure post-transaction from April to June 2014 will be submitted in February 2015.
- On December 24, the Company announced that it had signed a distribution agreement with Turkish-based Tani Medikal. This was the first of two distributor agreements that have been entered into to access significant markets through Indian and Turkish-based distributors.
- RHS training conducted at Morula IVF in Jakarta has been successfully completed in January 2015 enabling the introduction of Pre-implantation Genetic Screening in Indonesia. Morula IVF anticipate offering PGS to their patients in April 2015, once they have fully implemented their in-house laboratory.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9380
michelle.fraser@rhsc.com.au

Donald Stephens
CFO and Company Secretary
DonaldStephens@hlbsa.com.au

About Reproductive Health Science

Reproductive Health Science is an advanced biotech company that has successfully developed a test to assess embryos for chromosomal abnormalities prior to implantation as part of an In-Vitro Fertilisation (IVF) cycle. The two component system has an immediate application to improve the success rate of IVF. The Company's lead product *EmbryoCollect™* is aimed at improving health and research outcomes through the application of its frontier technologies with the initial primary focus of improving IVF success. Launched in 2014, *EmbryoCollect™* contains reagents for 20 tests at a list price of AUD\$3,600 per kit.

Reproductive Health Science Ltd.
ACN 010 126 708
ASX: RHS

Issued Capital
51.13 million shares
5.88 million options

Registered Office
Level One, BioSA Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9380
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Directors
Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Donald Stephens
Dr Michelle Fraser (CEO)

**Finance Officer
& Company Secretary**
Donald Stephens

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

REPRODUCTIVE HEALTH SCIENCE LIMITED

ABN

84 010 126 708

Quarter ended ("current quarter")

31 December 2014

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (twelve months) \$A'000
1.1	Receipts from customers		
1.2	Payments for		
	(a) staff costs	(199)	(809)
	(b) advertising & marketing	(10)	(27)
	(c) research & development	(50)	(116)
	(d) leased assets	(42)	(238)
	(e) other working capital	(172)	(326)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	29	39
1.5	Interest and other costs of finance paid	-	(5)
1.6	Income taxes paid	-	-
1.7	Other (provide details if material)	-	-
	Net operating cash flows	(444)	(1,482)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'ooo	Year to date (nine months) \$A'ooo
1.8 Net operating cash flows (carried forward)	(444)	(1,482)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(65)	(157)
(e) other non-current assets (bond refund)	10	10
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets (sale of tenement)	-	83
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	(55)	(64)
1.14 Total operating and investing cash flows	(499)	(1,546)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	3,000
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	100
1.18 Repayment of borrowings	-	(75)
1.19 Dividends paid	-	-
1.20 Other (Capital raising costs)	-	(508)
1.21 Cash acquired from deemed subsidiary *	-	331
Net financing cash flows	-	2,848
Net increase (decrease) in cash held	(499)	1,302
1.21 Cash at beginning of quarter/year to date	2,018	217
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	1,519	1,519

* Due to the nature of the reverse acquisition, RHS Subsidiary Pty Ltd (formerly Reproductive Health Science Pty Ltd, 'RHS Sub') is deemed to have acquired Reproductive Health Science Ltd (formerly AO Energy Ltd, 'RHS') for accounting purposes. Accordingly, the cash acquired contained within the cash flow statement represents the cash on hand in RHS on 2 April 2014 and the prior quarters cash outflow has been restated to represent RHS Sub's net cash outflow for the period.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	95
1.25	Aggregate amount of loans to the parties included in item 1.11	
1.26	Explanation necessary for an understanding of the transactions Executive director salary, directors fees and superannuation.	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	
3.2	Credit standby arrangements	

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	169	118
4.2	Deposits at call	1,350	1,900
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		1,519	2,018

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity		
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets		
5.5	Nature of business		

+ See chapter 19 for defined terms.

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here: Date: 30 January 2015
Donald Stephens
Company secretary

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.